z-logo
open-access-imgOpen Access
A Transformation-specific Polypeptide Distinct from Heat Shock Proteins is Induced by Herpes Simplex Virus Type 2 Infection
Author(s) -
Robert E. Hewitt,
Morag A. Grassie,
David McNab,
Anne Orr,
J.-F. Lucasson,
J. C. M. Macnab
Publication year - 1991
Publication title -
journal of general virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.55
H-Index - 167
eISSN - 1465-2099
pISSN - 0022-1317
DOI - 10.1099/0022-1317-72-12-3085
Subject(s) - biology , herpes simplex virus , heat shock protein , virology , monoclonal antibody , transformation (genetics) , antiserum , virus , epitope , immunoprecipitation , simplexvirus , microbiology and biotechnology , antibody , herpesviridae , immunology , biochemistry , gene , viral disease
A tumour-specific polypeptide designated U90 is one of a set of polypeptides which are encoded by the host cell and are specific for the transformed cell state, being immunoprecipitated by the sera of tumour-bearing animals. The interest in these tumour-specific polypeptides centres on the finding that they are also recognized by antisera raised against herpes simplex virus type 2 (HSV-2)-infected cells, implying some role for HSV-2 in tumorigenesis. The peptide map of HSV-2-induced U90 is indistinguishable from that of U90 present in uninfected tumour cells, including mouse cells transformed by human papillomavirus type 16. In tumour cells, U90 is located principally in the plasma membrane fraction and cannot be induced by heat shock, glucose starvation, or treatment with tunicamycin or calcium ionophore. U90 is not related to either the heat shock protein of Mr 90,000 (HSP90) or the glucose-related polypeptide of Mr 94,000 (GRP94) as determined by peptide mapping and the use of monospecific, monoclonal and antipeptide antibodies. This suggests that U90 is a novel transformation-specific protein which can be induced by infection with HSV-2.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here